Renal Denervation Session

Marriott Marquis, Carnegie Meeting Room, 5th Floor

Katherine J. Kunkel, MD

Raymond R. Townsend, MD

• Latest Hypertension Control Rates, Trends, and Current Targets
• Factors Influencing Control Rates, Including Medication Adherence
• Implications for Current Control Rates, Including Morbidity and Mortality Associated with Uncontrolled Hypertension
• Importance of Team-Based Approach for HTN Care
• Need for RF RDN as a New Complementary Treatment Option and Introduce FDA Approved Indication for Use

Katherine J. Kunkel, MD

• Renal Anatomy and Physiology of Renal Arteries, Mechanism of Action for  RF RDN, and Underlying Physiological Principles
• Key Components of the Symplicity RDN System
• Totality of Evidence Demonstrating the Short and Long-Term Efficacy and  Safety of RF RDN
• Published Consensus Statements
• Criteria for Selecting Appropriate Candidates for the RDN Procedure

Taisei J. Kobayashi, MD

Pre-Procedure Preparation:

• Steps to Prepare for the Procedure, Including Necessary Tests and Evaluations
• Patient Expectation

Procedure Execution:

• Step-by-Step Guide on Performing the Procedure
• Renal Anatomy Considerations

Post-Procedure Follow-Up:

• Monitoring and Managing the Patient Post-Procedure

Taisei J. Kobayashi, MD

Raymond R. Townsend, MD; Katherine J. Kunkel, MD

• Real World Patient Selection; Raymond Townsend, MD (10 min)
• Case Studies; Katherine J. Kunkel, MD (10 min)
• Discussion (10 min) 

Ruth Fisher, MBA; Robin Flint; Prakash Krishnan, MD

• Reimbursement Landscape and Resources; Robin Flint, MS, Sr. Regional Economic Manager, Medtronic (10 mins)
• Partnering with Administration on New Therapies; Ruth Fisher, MBA, VP Heart & Vascular Imaging, Cone Health (20 mins)
• Mt. Sinai Integration to Date; Prakash Krishnan, MD (15 mins)              

Prakash Krishnan, MD